And in the fourth quarter, we submitted for regulatory approval for the first in-human study for AVess, our arteriovenous accessed drug-coated balloon.
Srdx qtr date trial#
We executed three 510(k) submissions for unique medical devices developed in-house and we initiated 59 US clinical sites for the TRANSCEND clinical trial and substantially accelerated study enrollment. We strengthened our innovative product pipeline with the acquisition of a novel and differentiated thrombectomy platform.
We signed an agreement with Abbott as our worldwide commercialization partner for our SurVeil drug-coated balloon. We also accomplished several key strategic initiatives that position us for this growth. Not only did we accomplish this goal by growing revenue 11% year-over-year in fiscal 2018, we believe that Surmodics is now positioned for sustained double-digit revenue growth into the future.
Srdx qtr date full#
First and foremost, we're a full year (ph) ahead of schedule on our previously stated goal to achieve consistent double-digit revenue growth by the end of fiscal 2019. Fiscal 2018 has been an exciting year for Surmodics with many significant accomplishments by our team. Thank you, Tim and good morning and thank you for joining us. Maharaj - President and Chief Executive Officer
I will now turn the call over to Gary Maharaj. A press release disclosing our quarterly results was issued earlier this morning and is available on our website at. This conference call is being webcast and is accessible through the Investor Relations section of the Surmodics website where the audio recording of the webcast will also be archived for future reference. Today's news release contains a reconciliation table to our GAAP results. We'll also refer to non-GAAP measures because we believe they provide useful information for our investors.
Srdx qtr date update#
Surmodics disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise. Please be advised that actual results could differ materially from those stated or implied by our forward-looking statements resulting from certain risks and uncertainties including those described in our SEC filings. These forward-looking statements are covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements regarding Surmodics' future financial and operating results or other statements that are not historical facts. Before we begin, I would like to remind you that during this call, we will make forward-looking statements. Good morning and welcome to Surmodics' fiscal 2018 fourth quarter earnings call. Arens - Vice President of Corporate Development and Strategy, Interim Vice President of Finance and Chief Fi
At this time, I would like to turn the conference over to Tim Arens. Good day, and welcome to the Surmodics Fourth Quarter 2018 Earnings Conference Call.
0 kommentar(er)
